Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 19, 2024
Abstract
Background
Triple-negative
breast
cancer
(TNBC)
is
characterized
by
the
absence
of
estrogen
and
progesterone
receptors,
lack
human
epidermal
growth
factor
receptor
2
(HER2)
expression.
Traditional
Chinese
medicine
(TCM)
has
demonstrated
promising
efficacy
in
treating
TNBC.
Objective
To
explore
mechanisms
pachymic
acid
(PA)
on
Methods
We
gained
Microarray
data
TNBC
from
Gene
Expression
Omnibus
(GEO).
The
related
targets
PA
were
predicted
screened
using
following
six
databases:
Swiss
Target,
HERB,
ETCM,
BATMAN,
HIT,
PharmMapper.
Verification
Effective
Targets
TCGA.
STRING
interaction
network
analysis
tool
was
used
to
create
Protein-Protein
Interaction
(PPI)
networks.
Enrichment
included
Ontology
(GO)
Kyoto
Encyclopedia
Genes
Genomes
(KEGG).
also
conducted
a
pan-cancer
analysis,
tumor
immune
microenvironment
molecular
docking.
Finally,
we
performed
cell
experimental,
cytotoxicity
assay,
apoptosis
proliferation
migration
invasion
assays.
Results
found
that
potential
for
TNBC,
with
TOP2A
likely
being
its
target,
platinum
drug
resistance
possibly
serving
as
KEGG
pathway
through
which
exerts
therapeutic
effects.
By
targeting
TOP2A,
involved
processes
such
nuclear
division,
chromosome
segregation,
mitotic
condensed
formation,
protein
C-terminus
binding.
may
exert
effects
microenvironment,
involving
elements
Dendritic
cells
activated,
Eosinophils,
Macrophages
M0,
M1,
T
CD4
memory
activated.
vary
across
different
subtypes
three
subtypes,
TNBC-BL1,
TNBC-Metaplastic,
TNBC-BL2,
are
respond
more
favorably.
Conclusion
Our
study
provides
compelling
evidence
holds
significant
promise
agent
primarily
action
influence
Pharmaceuticals,
Год журнала:
2024,
Номер
17(10), С. 1333 - 1333
Опубликована: Окт. 5, 2024
Glaucoma
is
a
progressive
optic
neuropathy
characterized
by
the
neurodegeneration
and
death
of
retinal
ganglion
cells
(RGCs),
leading
to
blindness.
Current
glaucoma
interventions
reduce
intraocular
pressure
but
do
not
address
neurodegeneration.
In
this
effort,
identify
new
pharmacological
targets
for
management,
we
employed
network
pharmacology
approach.
Biomedical Engineering and Computational Biology,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 1, 2024
Upadacitinib,
a
selective
Janus
associated
kinase
1
(JAK-1)
inhibitor,
can
be
prescribed
particularly
for
the
clinical
treatment
with
Crohn's
disease
or
rheumatoid
arthritis.
It
is
clinically
observed
that
upadacitinib
has
been
found
potential
therapeutic
effectiveness
on
Sjogren's
syndrome
(SS).
However,
anti-SS
targets
and
mechanisms
involved
in
remain
uninvestigated.
